The first and only platform in newborn screening for lysosomal storage disorders with FDA authorization and CE mark.

SEEKER is a high throughput laboratory solution that quantitatively measures the activity of lysosomal enzymes from newborn dried blood spot specimens. Reduced activity of these enzymes may be indicative of Mucopolysaccharidosis Type I (MPS I), Pompe, Gaucher or Fabry disease.

Everything your lab needs for LSD screening in one small workstation.

SEEKER Brochure


“FDA clearance enables state laboratories to confidently implement testing while minimizing the validation effort resulting in a cost effective implementation.”